AVIR (STOCKS)
Atea Pharmaceuticals, Inc. Common Stock
$4.460000
+0.300000 (+7.21%)
Prev close: $4.160000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jean-Pierre Sommadossi
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $348.89M
- Employees
- 56
- P/E (TTM)
- -2.34
- P/B (TTM)
- 1.03
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
4
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.53 | $-0.45 | -0.0812 | -18.09% |
|
Jun 2025 (Q2)
|
$-0.44 | $-0.42 | -0.0167 | -3.95% |
|
Mar 2025 (Q1)
|
$-0.40 | $-0.42 | +0.0182 | +4.35% |
|
Dec 2024 (Q4)
|
$-0.40 | $-0.38 | -0.0226 | -5.99% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $164.98M |
| Depreciation and Amortization | $416.00K |
| Research and Development | $125.88M |
| Other Operating Expenses | $38.69M |
| Operating Income/Loss | -$164.98M |
| Income/Loss From Continuing Operations After Tax | -$147.03M |
| Income/Loss From Continuing Operations Before Tax | -$146.19M |
| Income Tax Expense/Benefit | $831.00K |
| Net Income/Loss | -$147.03M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$147.03M |
| Net Income/Loss Available To Common Stockholders, Basic | -$147.03M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.78 |
| Diluted Earnings Per Share | -$1.78 |
| Basic Average Shares | 163,568,070 |
| Diluted Average Shares | 163,568,070 |
| Assets | $342.96M |
| Current Assets | $336.14M |
| Cash | $329.30M |
| Other Current Assets | $6.84M |
| Noncurrent Assets | $6.83M |
| Fixed Assets | $561.00K |
| Other Non-current Assets | $6.26M |
| Liabilities | $27.18M |
| Current Liabilities | $20.18M |
| Accounts Payable | $3.52M |
| Wages | $4.89M |
| Other Current Liabilities | $11.77M |
| Noncurrent Liabilities | $7.01M |
| Equity | $315.78M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $315.78M |
| Liabilities And Equity | $342.96M |
| Net Cash Flow From Operating Activities | -$134.21M |
| Net Cash Flow From Operating Activities, Continuing | -$134.21M |
| Net Cash Flow From Investing Activities | $138.83M |
| Net Cash Flow From Investing Activities, Continuing | $138.83M |
| Net Cash Flow From Financing Activities | -$25.75M |
| Net Cash Flow From Financing Activities, Continuing | -$25.75M |
| Net Cash Flow | -$21.12M |
| Net Cash Flow, Continuing | -$21.12M |
| Comprehensive Income/Loss | -$147.43M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$147.43M |
| Other Comprehensive Income/Loss | -$403.00K |